GSK3β has also become an important drug target in anticancer therapy (Kingwell, 2018), Obesity-Induced White Adipose Tissue Inflammation (Wang et al., 2018), diabetes (Mussmann et al., 2007), and central nervous system diseases (Wang et al., 2017; Wickens et al., 2017). Here, GSK3B is linked to central nervous system disorder.